<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Pitt, Bertram</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Spironolactone Misses Primary Endpoint in TOPCAT</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-22</style></pages><abstract><style  face="normal" font="default" size="100%">Spironolactone treatment of heart failure (HF) with preserved ejection fraction (HFpEF) did not significantly reduce cardiovascular death, hospitalization due to HF, or resuscitated cardiac arrest compared with placebo. This article presents updated data from the Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function trial [TOPCAT; Shah SJ et al. Circ Heart Fail 2012].</style></abstract><number><style face="normal" font="default" size="100%">12</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>